Mike Bond advises public and private companies and institutional equity investors on private equity and other M&A transactions including takeover offers, strategic investments, and joint ventures, often with an international dimension.
He served as a member of Latham & Watkins’ Executive Committee until 2016.
Mr. Bond's representative transactions include advising:
-
Onex Partners V on its investment in Convex Group Limited, a specialty property and casualty insurance company headquartered in Bermuda
-
La Caisse de dépôt et placement du Québec (CDPQ) on its partnership with Generation Investment Management LLP and investment in FNZ, a global fintech company
-
Onex Corporation in connection with its acquisition of KidsFoundation, a leading Dutch childcare provider
-
The Carlyle Group on the €10.1 billion acquisition by
Carlyle and GIC of AkzoNobel's Specialty Chemicals business
- Leonard Green & Partners on the acquisition of CPA Global from Cinven
- The Carlyle Group and The Nature’s Bounty Co. on the £1.77 billion sale of Holland & Barrett, one of Europe’s largest health and wellness retailers
- Canada Pension Plan Investment Board on its acquisition of an approximate 48% stake in GlobalLogic Inc., a global leader in digital product development services
- Onex Corporation on its £1.35 billion acquisition of Parkdean Resorts, a leading UK operator of caravan holiday parks
- Onex Corporation on its US$680 million acquisition of Survitec Group, a market-leading provider of mission-critical marine, defense, and aerospace survival equipment
- The Carlyle Group on its US$700 million acquisition of Dealogic, a provider of software and data platforms to investment banking industry
- Onex Corporation on its €3.75 billion acquisition of SIG Combibloc Group AG, the second largest provider of aseptic carton packaging globally
- The Carlyle Group on the acquisition of Addison Lee, a provider of private hire vehicles and courier services
- Watson Pharmaceuticals on its £4.5 billion acquisition of Actavis Group creating the world’s third-largest generic pharmaceutical company
- Novo A/S on the sale of Archimedes Pharma, a UK-based pharmaceutical company, to ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co
- Qatar Holding LLC (a wholly owned subsidiary of Qatar Investment Authority) on its acquisition of The Harrods Group
- Charterhouse Capital Partners on its LBO of The Card Factory for an undisclosed sum